NEW YORK, Feb. 7, 2019 /PRNewswire/ -- Q BioMed Inc. (QBIO), is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company.
Expecting several corporate developments and news events, the Company's investor relations consulting firm engaged a new sub-contracted service provider on January 1, 2019, to assist in presenting the Company to a broader audience. The third-party service provider, Platinum Vlll Investment and Media LLC, has several outlets that it contracts with to provide visibility to its clients, including the Company, using its various subscriber bases. The Company first became aware of third-party promotional content on January 17, 2019. Neither the Company nor any of its officers, directors, management and scientific consultants or controlling shareholders had any editorial input into any of the content created by any third-party providers. While the Company has not seen and cannot validate all claims made by all unrelated parties, those that have been brought to our attention by OTC Markets do not appear to have any materially false or misleading statements and rely on historical public information, previously made statements, independent analyst reports and Company issued press releases. We assume that the increased exposure has resulted in some increase in the trading volume of the our stock, however, it is not unusually high and is within our typical trading averages over the last twenty-four months.
To our knowledge and after inquiry by management, none of our officers, directors, insiders, control persons or third-party contractors have sold or purchased any shares in the open market in the last 90 days.
Over the last 12 months, we have engaged the following firms:
- Cayvan Consulting
- Acorn Management Partners
- Infinite Growth Concepts
- Corporate Profile
- Financial Buzz Media
- Proactive Investors Inc.
- Investing News Network
- Chedwick Marketing
- Landon Capital
- JV Public Relations
As requested by the OTC Markets, below is a summary of any shares or convertible instruments allowing conversion of equity securities at prices constituting a discount to the current market rate at the time of issuance:
On September 21, 2018, Q BioMed Inc. entered into a securities purchase agreement with an accredited investor (YA II CF, Ltd.) to place convertible debentures with a maturity date of eighteen months after the issuance thereof in the aggregate principal amount of up to $4,000,000. The first closing transaction occurred on September 21, 2018 when we issued a debenture for $2,000,000. The second closing occurred on November 1, 2018 when we issued another debenture for $2,000,000 (collectively, "YA Debentures"). The YA Debentures bear interest at the rate of 5.5% per annum and the Company paid an upfront fee equal to 2.5% of the amount of the debentures, which amount was deducted from the proceeds.
The YA Debentures may be converted at any time on or prior to maturity at the lower of $4.00 or 93% of the average of the four lowest daily volume weighted average price during the 10 consecutive trading days immediately preceding the conversion date, provided that as long as we are not in default under a YA Debenture, the conversion price may never be less than $2.00. An effective registration statement on Form S-1 covers the conversion shares. As of today's date, no conversions have been made and the total $4,000,000 is outstanding.
Q BioMed endeavours to provide accurate updates and relevant information through our news releases. We encourage all investors to do their own due diligence when investing in any stock and suggest that they rely more on Company issued releases and SEC filings rather than any third party source.
About Q BioMed Inc.
Q BioMed aims to accelerate the monetization of biomedical technologies through rapid innovation and collaborative partnerships with industry leading researchers. Q BioMed believes its assets in oncology, vascular disease, and rare orphan diseases address unmet medical needs and large markets. The Company's FDA approved, non-opioid drug Metastron, which relieves cancer bone pain, is expected to begin generating revenues in 2019. Metastron is also approved for sale in 21 other countries. In addition to treating pain, Metastron has shown evidence of treating the cancer itself and extending survival. Q BioMed plans to conduct Phase IV trials to support label extension and cancer survival benefit using Metastron.
For more information please visit www.qbiomed.com.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Q BioMed Inc.